332
CHICAGO, IL – Reuters reports the FDA on Monday approved Novo Nordisk’s weight-loss pill, “giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.
The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy.”
According to Reuters, the pill was “approved for chronic weight management in adults with obesity or overweight and at least one related health condition, broadening the potential patient pool at a time when insurers, employers and governments are wrestling with spiraling health care costs related to obesity.”
Media Release/AMA Morning Rounds
